SecBot SecBot
SECBOTREPLAY Home › Report › SNDX

SNDX · Syndax Pharmaceuticals filed DEFA14A definitive additional proxy…

Syndax Pharmaceuticals Inc · DEFA14A filed Jun 4, 2026 at 08:36 ET

At the news

NEUTRALIMPACT 4/10

DEFA14A filed Jun 4, 2026 at 08:36 ET

Syndax Pharmaceuticals filed DEFA14A definitive additional proxy materials urging shareholders to vote FOR Proposal No. 4 (2026 Equity Incentive Plan) at the June 10, 2026 annual meeting. The filing rebuts ISS's against recommendation by correcting the share count for the 5,060,185 shares canceled upon the 2015 Plan's expiration, reducing total potential basic dilution from ISS's 35.51% to 27.93%. The plan requests 7.2 million new shares with investor-friendly features (no evergreen, no repricing, clawback policy, 12-year modeled capacity).

  • Annual meeting scheduled June 10, 2026; board unanimously recommends FOR all proposals, specifically Proposal No. 4 (2026 Equity Incentive Plan)
  • ISS recommended against Proposal No. 4; Glass Lewis recommended FOR
  • 2026 Plan requests 7,200,000 new shares; replaces expired 2015 Plan
  • 5,060,185 shares canceled upon 2015 Plan expiration in March 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access